|
|
|
| Diagnostic value of FIB, D-dimer and serum CysC in bone metastasis of prostate cancer |
| LI Xuanyu1 HAO Lin2 HAN Conghui1▲ |
1.Graduate School, Jiangsu University, Jiangsu Province, Zhenjiang 212000, China;
2.Department of Urology, Xuzhou Central Hospital, Jiangsu Province, Xuzhou 221009, China |
|
|
|
Abstract Objective To investigate the diagnostic value of Fibrinogen (FIB), D-dimer, and serum CystatinC (CysC) levels in bone metastasis of prostate cancer (PCa). Methods Clinical data of 207 patients initially diagnosed with PCa in Xuzhou Central Hospital of Jiangsu Province from June 2016 to January 2019 were retrospectively collected, and they were divided into 102 patients with bone metastasis and 105 patients without bone metastasis according to bone scanning and imaging examination. Intergroup control study, univariate, and multivariate logistic regression analysis were used to evaluate the diagnostic value of FIB, D-dimer, CysC and clinical indicators for PCa bone metastasis. Receive operating characteristic curve was used to evaluate the clinical significance of FIB, D-dimer, CysC, and their combined indexes in the diagnosis of PCa bone metastasis. Results The levels of FIB, D-dimer, and CysC in bone metastasis group were higher than those in non-metastasis group (P ＜ 0.05), and the multivariate regression analysis showed that the three factors were independent risk factors for PCa bone metastasis (OR > 1, P ＜ 0.05). The combined index level was the best, followed by single index CysC, D-dimer, and FIB, which showed good diagnostic value (AUC > 0.5, P ＜ 0.05). Conclusion FIB, D-dimer, and CysC are closely related to bone metastasis of PCa, and can be used in conjunction with clinical T stage and Gleason score to evaluate bone metastasis of PCa, which has high clinical value.
|
|
|
|
|
|
[1] Sung H，Ferlay J，Siegel RL，et al. Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[2] Dinatale A，Fatatis A. The Bone Microenvironment in Prostate Cancer Metastasis [J]. Adv Exp Med Biol，2019，1210：171-184.
[3] Zhu Z，Wen Y，Xuan C，et al. Identifying the key genes and microRNAs in prostate cancer bone metastasis by bioinformatics analysis [J]. FEBS Open Bio，2020，10（4）：674-688.
[4] Caglic I，Kovac V，Barrett T. Multiparametric MRI - local staging of prostate cancer and beyond [J]. Radiol Oncol，2019，53（2）：159-170.
[5] Caliskan S，Sungur M. Fibrinogen and D-dimer levels in prostate cancer：Preliminary results [J]. Prostate Int，2017， 5（3）：110-112.
[6] Wang FM，Xing NZ. Systemic Coagulation Markers Especially Fibrinogen Are Closely Associated with the Aggressiveness of Prostate Cancer in Patients Who Underwent Transrectal Ultrasound-Guided Prostate Biopsy [J]. Dis Markers，2021，2021：8899994.
[7] 王晶，王欢欢，张绍城.前列腺癌患者血清胱抑素C水平的实验室评价[J].国际检验医学杂志，2016，37（12）：1697-1698.
[8] 王雪安，牛倩，黄敏，等.前列腺癌患者血清胱抑素C水平与临床评分相关性研究[J].临床泌尿外科杂志，2021， 36：182-185.
[9] Allin KH，Bojesen SE，Nordestgaard BG. Inflammatory biomarkers and risk of cancer in 84，000 individuals from the general population [J]. Int J Cancer，2016，139（7）：1493-1500.
[10] Xie GS，Li G，Li Y，et al. Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients [J]. Chin Med J （Engl），2019，132（22）：2684-2689.
[11] 朱惠，陶吴东，黄彬，等.血浆纤维蛋白原与前列腺癌骨转移的相关性及诊断价值研究[J].中华腔镜泌尿外科杂志（电子版），2021，15（2）：135-138.
[12] Bagoly Z. Cancer and thrombosis：a fresh look at an old story [J]. Thromb Res，2015，136（1）：1-2.
[13] Wen J，Yang Y，Ye F，et al. The preoperative plasma fibrinogen level is an independent prognostic factor for overall survival of breast cancer patients who underwent surgical treatment [J]. Breast，2015，24（6）：745-750.
[14] Yamagata K，Fukuzawa S，Ishibashi-Kanno N，et al. The Association between D-Dimer and Prognosis in the Patients with Oral Cancer [J]. Dent J （Basel），2020，8（3）：84.
[15] 王志杰，刘秉乾，武玉东.外周凝血指标对初诊前列腺癌患者骨转移风险的预测价值[J].现代泌尿外科杂志，2021，26（2）：135-138.
[16] Jiborn T，Abrahamson M，Gadaleanu V，et al. Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation [J]. BJU Int，2006，98（1）：189-196.
[17] Leto G，Sepporta MV. The potential of cystatin C as a predictive biomarker in breast cancer [J]. Expert Rev Anticancer Ther，2020，20（12）：1049-1056.
[18] Guo K，Chen Q，He X，et al. Expression and significance of Cystatin-C in clear cell renal cell carcinoma [J]. Biomed Pharmacother，2018，107：1237-1245.
[19] Liu Q，Russell MR，Shahriari K，et al. Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features [J]. Cancer Res，2013，73（11）：3297-3305.
[20] Abuzallouf S，Dayes I，Lukka H. Baseline staging of newly diagnosed prostate cancer：a summary of the literature [J]. J Urol，2004，171（6 Pt 1）：2122-2127.
[21] Briganti A，Suardi N，Gallina A，et al. Predicting the risk of bone metastasis in prostate cancer [J]. Cancer Treat Rev，2014，40（1）：3-11. |
|
|
|
